HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 386 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,901,745 | -12.8% | 285,386 | -17.7% | 0.00% | -33.3% |
| Q2 2023 | $12,502,223 | -13.7% | 346,610 | -8.6% | 0.00% | +50.0% |
| Q1 2023 | $14,486,460 | -18.0% | 379,326 | +22.1% | 0.00% | -60.0% |
| Q4 2022 | $17,676,440 | +18.0% | 310,658 | -18.0% | 0.01% | +25.0% |
| Q3 2022 | $14,983,000 | +50.1% | 378,943 | +67.0% | 0.00% | +100.0% |
| Q2 2022 | $9,985,000 | -2.3% | 226,931 | -11.5% | 0.00% | +100.0% |
| Q1 2022 | $10,224,000 | -60.0% | 256,390 | -59.7% | 0.00% | – |
| Q4 2021 | $25,570,000 | +79.8% | 635,856 | +81.9% | 0.00% | -100.0% |
| Q3 2021 | $14,219,000 | -10.7% | 349,531 | -0.3% | 0.00% | 0.0% |
| Q2 2021 | $15,928,000 | +46.5% | 350,744 | +34.5% | 0.00% | +100.0% |
| Q1 2021 | $10,870,000 | -56.1% | 260,740 | -55.0% | 0.00% | 0.0% |
| Q4 2020 | $24,742,000 | +367.9% | 579,332 | +188.0% | 0.00% | – |
| Q3 2020 | $5,288,000 | -41.3% | 201,170 | -40.2% | 0.00% | -100.0% |
| Q2 2020 | $9,013,000 | +94.6% | 336,188 | +30.6% | 0.00% | +100.0% |
| Q1 2020 | $4,631,000 | -46.0% | 257,466 | -46.8% | 0.00% | -66.7% |
| Q4 2019 | $8,575,000 | +14.9% | 483,658 | +0.5% | 0.00% | 0.0% |
| Q3 2019 | $7,461,000 | -73.8% | 481,088 | -71.0% | 0.00% | 0.0% |
| Q2 2019 | $28,510,000 | +415.1% | 1,659,550 | +382.7% | 0.00% | 0.0% |
| Q1 2019 | $5,535,000 | -31.0% | 343,800 | -37.3% | 0.00% | -25.0% |
| Q4 2018 | $8,017,000 | -2.6% | 548,027 | +21.0% | 0.00% | +33.3% |
| Q3 2018 | $8,229,000 | -25.2% | 452,891 | -30.6% | 0.00% | -25.0% |
| Q2 2018 | $11,002,000 | -8.9% | 652,143 | +5.8% | 0.00% | 0.0% |
| Q1 2018 | $12,074,000 | -41.1% | 616,352 | -39.0% | 0.00% | -42.9% |
| Q4 2017 | $20,482,000 | +17.7% | 1,010,991 | +0.9% | 0.01% | 0.0% |
| Q3 2017 | $17,408,000 | +1.7% | 1,002,200 | -25.0% | 0.01% | -12.5% |
| Q2 2017 | $17,124,000 | +19.2% | 1,335,700 | +20.5% | 0.01% | +14.3% |
| Q1 2017 | $14,363,000 | +95.7% | 1,108,200 | +49.2% | 0.01% | +75.0% |
| Q4 2016 | $7,338,000 | -20.4% | 742,786 | -2.6% | 0.00% | -20.0% |
| Q3 2016 | $9,214,000 | +52.1% | 762,700 | +8.6% | 0.01% | +66.7% |
| Q2 2016 | $6,058,000 | -24.4% | 702,002 | -17.0% | 0.00% | -25.0% |
| Q1 2016 | $8,011,000 | -71.2% | 845,900 | -47.3% | 0.00% | -69.2% |
| Q4 2015 | $27,835,000 | +63.0% | 1,606,133 | +26.3% | 0.01% | +62.5% |
| Q3 2015 | $17,077,000 | -25.1% | 1,271,536 | +25.9% | 0.01% | -20.0% |
| Q2 2015 | $22,802,000 | +154.4% | 1,009,867 | +60.9% | 0.01% | +100.0% |
| Q1 2015 | $8,963,000 | +47.4% | 627,693 | -0.4% | 0.01% | +150.0% |
| Q4 2014 | $6,082,000 | -43.3% | 630,288 | -46.5% | 0.00% | -50.0% |
| Q3 2014 | $10,722,000 | -5.3% | 1,178,176 | +2.8% | 0.00% | 0.0% |
| Q2 2014 | $11,327,000 | -25.9% | 1,146,511 | -4.8% | 0.00% | -42.9% |
| Q1 2014 | $15,295,000 | -23.9% | 1,203,869 | -10.3% | 0.01% | -22.2% |
| Q4 2013 | $20,109,000 | +89.9% | 1,341,468 | +39.9% | 0.01% | +50.0% |
| Q3 2013 | $10,588,000 | +102.8% | 959,127 | +46.1% | 0.01% | +100.0% |
| Q2 2013 | $5,221,000 | – | 656,647 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 14,092,771 | $256,066,000 | 16.64% |
| BB BIOTECH AG | 8,247,860 | $149,864,000 | 3.97% |
| MSD Partners, L.P. | 2,245,000 | $40,792,000 | 3.07% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 428,633 | $5,969,000 | 2.84% |
| First Light Asset Management, LLC | 885,523 | $16,090,000 | 2.60% |
| SNYDER CAPITAL MANAGEMENT L P | 2,387,350 | $43,378,000 | 1.93% |
| Sterling Global Strategies LLC | 22,000 | $400,000 | 1.74% |
| Taylor Wealth Management Partners | 221,380 | $4,022,000 | 1.71% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,228,399 | $167,680,000 | 1.68% |
| DOHENY ASSET MANAGEMENT /CA | 124,393 | $2,260,000 | 1.18% |